Free Newsletter
FEATURES >> The most interesting logos in Pharma
FDA hands Crestor a fighting chance
In the battle of the cholesterol meds, Crestor just got a new weapon. The FDA approved AstraZeneca's application to market the drug not just for lowering cholesterol, but to treat hardening of the arteries, too. It's the first statin to win approval for that indication.
It's an important coup for AstraZeneca, which has been looking for an edge for Crestor--a late entry onto the statin field. As you know, those efforts were compromised earlier this week by research showing the drug didn't alleviate heart failure. And last week, AstraZeneca announced it was facing a generic challenge to Crestor's patents.
- check out the release from AstraZeneca
- read the report from The Times
Related Articles:
AZ's Crestor flubs key heart failure trial. Report
AZ hit with Crestor patent challenge. Report
Crestor less safe than competing statins. Report
Top 5 layoffs of 2007--AstraZeneca. Report
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities



SHARE
WITH: